Notably, RMC‐6291 seems to be also effective in Ras‐dependent RAL‐GEF and AKT‐mTOR signaling.[42] RMC‐6291 is currently tested in clinical trials with a focus on lung and colorectal cancers (NCT05462717, NCT06128551, and NCT06162221). This evidence concerns the gene MTOR and colorectal cancer.